A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies (Q33387006)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies |
scientific article |
Statements
1 reference
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies (English)
1 reference
Robert Z Orlowski
1 reference
Owen A O'Connor
1 reference
A Keith Stewart
1 reference
Marcy Vallone
1 reference
Christopher J Molineaux
1 reference
Lori A Kunkel
1 reference
John F Gerecitano
1 reference
10 November 2009
1 reference
1 reference
15
1 reference
22
1 reference
7085-7091
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference